Nemtabrutinib

Richter Transformation

Roswell Park Cancer InstituteSmall moleculePhase 2Active

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 81/ 100

Competitive context

56 Active assets in the Richter Transformation cohort.

Asset / Sponsor	Phase	Rating
Obinutuzumab Christine Ryan	Phase 2	BB
Venetoclax Northwestern University	Phase 2	BB
Ibrutinib City of Hope Medical Center	Phase 2	BB
Inno-206 SWOG Cancer Research Network	Phase 3	BB
PREDNISONE TABLETS SWOG Cancer Research Network	Phase 3	BB

View all 50 →

Same molecule, other indications

Nemtabrutinib is also rated in:

B-cell chronic lymphocytic leukemiaDormant

BB

Indicative ·

64 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

B

Indicative ·

60 / 100

Waldenstrom macroglobulinemiaDormant

B

Indicative ·

58 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.